Biopharmaceutical Company Reveals Major Preclinical Data For Cancer Treatment

In a groundbreaking announcement at the American Association for Cancer Research (AACR) Annual Meeting 2024, IN8bio, Inc., a clinical-stage biopharmaceutical company, unveiled new preclinical data that could potentially revolutionize cancer treatment as we know it. Their innovative non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell (nsCAR) platform, known as INB-300, has shown remarkable selectivity in targeting leukemia cells while sparing healthy ones. This advancement is not just a leap forward in cancer therapy; it's a beacon of hope for millions around the globe fighting this relentless disease. $In8bio(INAB.US)$